Bayer to cut price of contraceptive implant in developing countries

Bayer has announced plans to cut the price of its contraceptive implant Jadelle for women in developing countries until 2023.

The Jadelle Access Programme will reduce the price of the implant by half to make this underutilised contraceptive method more affordable and accessible to women in some of the world's poorest nations, expanding their choice of options.

Data from the Reproductive Health Supply Coalition has indicated that the demand for implants is increasing continuously in these countries, with family planning recognised as a key priority for better health and wellbeing worldwide.

Bayer has nearly 50 years of expertise in the field of family planning and has supplied hormonal contraceptive methods to partners in international development cooperation at a preferential price for some time.

Dieter Weinand, member of the board of management of Bayer and president of its pharmaceuticals division, said: "Our Jadelle Access Programme widens the contraceptive options available to women living in poor countries around the world, so they can choose a method that best suits their needs."

This comes after the firm recently filed for EU and US regulatory approval for LCS-16, its new low-dose levonorgestrel-releasing intrauterine contraceptive system.